US 11912780
Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
granted A61KA61K2039/505A61K40/10
Quick answer
US patent 11912780 (Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies) held by Actinium Phamaceuticals, Inc. expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Actinium Phamaceuticals, Inc.
- Grant date
- Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K2039/505, A61K40/10, A61K40/22, A61K40/416